Protagonist Therapeutics (PTGX) Non-Current Assets (2015 - 2026)

Protagonist Therapeutics has disclosed Non-Current Assets across 12 years of filings, most recently posting $84.0 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $84.0 million, down 38.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $451.0 million (up 46.06% YoY), and the FY2025 annual result was $11.7 million, down 7.28% from the prior year.
• Non-Current Assets came in at $84.0 million for Q1 2026 at Protagonist Therapeutics, up from $11.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $136.3 million in Q1 2025 to a low of $1.7 million in Q1 2024.
• The 5-year median for Non-Current Assets is $6.8 million (2022), against an average of $40.3 million.
• Across the five-year window, Non-Current Assets tumbled 87.78% in 2022 and surged 7809.0% in 2025, its largest moves.
• Protagonist Therapeutics' Non-Current Assets stood at $4.6 million in 2022, then sank by 53.55% to $2.1 million in 2023, then jumped by 486.64% to $12.6 million in 2024, then retreated by 7.28% to $11.7 million in 2025, then surged by 618.66% to $84.0 million in 2026.
• The last three Non-Current Assets figures came in at $84.0 million (Q1 2026), $11.7 million (Q4 2025), and $115.3 million (Q3 2025), per Business Quant data.